Informazioni sul prodotto
- Ubrelvy
- Spiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide, 1′,2′,5,7-tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxo-, (3′S)-
- (3′S)-1′,2′,5,7-Tetrahydro-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2′-oxospiro[6H-cyclopenta[b]pyridine-6,3′-[3H]pyrrolo[2,3-b]pyridine]-3-carboxamide
- MK 1602
Ubrogepant is a small-molecule drug that is used to treat migraine. It inhibits the activity of a receptor called CGRP, which is associated with the development of migraine headaches. Ubrogepant has been shown to be effective in treating chronic cough and has also been found to be safe for long-term use. The drug does not have significant toxicity or major side effects. Ubrogepant may increase the risk of bleeding and gastrointestinal disorders when used with nonsteroidal anti-inflammatory drugs (NSAIDs).
Proprietà chimiche
Richiesta tecnica su: 3D-FU165699 Ubrogepant
Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.
